Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DigiFab to Prevent Post-operative AKI in CABG Patients
NCT03810417Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2019
- Primary completion
- Apr 2024
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of digoxin immune fab in acute kidney injury (AKI) (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Renal Function at 72 hours. Started Jul 2019; status: completed.
02
Drugs
digoxin immune fab
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03810417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810417.